Allovir Inc reports results for the quarter ended in March - Earnings Summary

Kalaris Therapeutics

06/05/2021 15:47

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss of 50
cents​​ per share for the quarter ended in March. The mean
expectation of four analysts for the quarter was for a loss
of 40 cents per share.
* Revenue was $0.00​​;  analysts expected $0.00.
* Allovir Inc's reported EPS for the quarter was a loss of 50
cents​.
* The mean earnings estimate of analysts had risen by about 8.5%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Allovir Inc shares had fallen by 7.1% this quarter and
lost 43.4% so far this year.
* The company reported a quarterly loss of $30.92 million.
* Wall Street's median 12-month price target for Allovir Inc is
$50.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 02:47 p.m. GMT. ​All
figures in US Dollars.​